ArticleJHEP reports : innovation in hepatology2026
The endonuclease MCPIP1 protects against liver cancer development in a sex-dependent manner by modulating β-catenin and CREB1.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsMonocyte chemoattractant protein-induced protein 1 (MCPIP1), encoded by ZC3H12A, is a negative regulator of inflammation and tumorigenesis. While its role has been implicated in various cancers, the function of MCPIP1 in hepatocellular carcinoma (HCC) remains poorly understood. This study explored the contribution of hepatocyte-specific MCPIP1 loss to HCC pathogenesis, highlighting its role in overcoming the inherent tumor resistance observed in female mice.
methodsLiver tissues (n ≥5 per group) and primary hepatocytes (n ≥3 per group) were evaluated using western blotting, immunohistochemistry, immunofluorescence, RNA sequencing and pathway-enrichment analysis. The expression levels of MCPIP1 in HCC were measured by quantitative reverse-transcription PCR. The results are presented as mean ± SD, Student's t or Mann‒Whitney U tests were used for statistical analysis of two groups. For more than two groups, ordinary two-way ANOVA was used.
resultsThe hepatocyte-specific loss of MCPIP1 markedly promoted fibrosis and tumorigenesis, particularly in female mice, disrupting the normal sex-related protection observed in the diethylnitrosamine model. As determined by next-generation sequencing and bioinformatics analysis, oncogenic and fibrotic programs, including the EMT, Wnt/β-catenin, and JAK/STAT3 pathways, were activated in MCPIP1 knockout livers. These molecular events activated β-catenin, c-Met, and IL-6/STAT3/NF-κB signaling, and they enhanced fibrotic remodeling. In MCPIP1-deficient hepatocytes, active β-catenin and CREB1 accumulated in the nucleus, and the expression of protumorigenic targets, such as Spp1, Tgfb2, and Adam17 increased. Moreover, MCPIP1 expression was significantly downregulated in human HCC tissues and correlated with tumor progression.
conclusionsMCPIP1 plays a protective role against inflammation-driven hepatocarcinogenesis, particularly in females, by restraining fibrotic remodeling and oncogenic signaling. The downregulation of MCPIP1 expression promotes a tumor-promoting microenvironment through the coordinated activation of the β-catenin, STAT3, and CREB1 pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.